Abstract: A vehicle body front structure includes a pop-up hood unit disposed on a front end portion of an enginehood of a vehicle body and configured to move upward above the enginehood by using a lift-up mechanism. The pop-up hood unit is deformable due to an input of an impact upon a collision with a target for protection. The pop-up hood unit is shaped as a plate that extends in a left-right direction of the vehicle body and has a plate surface having an inclination angle that is variable relative to a horizontal plane.

Abstract: An air bag device has an inflator and a bag unit configured to be deployed on a front part of a vehicle body with a gas supplied from the inflator. The bag unit includes a first bag, a second bag, and a connector, which are annularly connected to one another, and when the bag unit is deployed, the first bag and the second bag are erected on the vehicle body into a mountain-like shape in such a way that the bag unit forms a substantially triangular shape as a whole.

Abstract: An airbag system includes a bag unit which deploys on an enginehood of a vehicle body by a gas from an inflator. The bag unit is divided into bags back and forth and right and left. The bags include adjacent bags communicating with each other through communication paths. The bags include at least one upright bag to be upright on at least one fender of left and right fenders of the vehicle body. A gas flows from a front bag of the bags located at a front side of the vehicle body through communication paths to a rear bag of the bags behind the front bag and the at least one upright bag on the side of the front bag.

Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1, 3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).

Abstract: An airbag system includes a bag unit which deploys on an enginehood of a vehicle body by a gas from an inflator. The bag unit is divided into bags back and forth and right and left. The bags include adjacent bags communicating with each other through communication paths. The bags include at least one upright bag to be upright on at least one fender of left and right fenders of the vehicle body. A gas flows from a front bag of the bags located at a front side of the vehicle body through communication paths to a rear bag of the bags behind the front bag and the at least one upright bag on the side of the front bag.

Abstract: A vehicle body front structure includes a pop-up hood unit disposed on a front end portion of an enginehood of a vehicle body and configured to move upward above the enginehood by using a lift-up mechanism. The pop-up hood unit is deformable due to an input of an impact upon a collision with a target for protection. The pop-up hood unit is shaped as a plate that extends in a left-right direction of the vehicle body and has a plate surface having an inclination angle that is variable relative to a horizontal plane.

Abstract: An air bag device has an inflator and a bag unit configured to be deployed on a front part of a vehicle body with a gas supplied from the inflator. The bag unit includes a first bag, a second bag, and a connector, which are annularly connected to one another, and when the bag unit is deployed, the first bag and the second bag are erected on the vehicle body into a mountain-like shape in such a way that the bag unit forms a substantially triangular shape as a whole.

Abstract: The present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing, as an active ingredient, 7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof, or 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).

Abstract: The present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing, as an active ingredient, 7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof, or 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).

Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).

Abstract: Compounds exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof: wherein A is selected from among a 3- to 10-membered heterocyclyl group, B is selected from among an amino group, and X is selected from N and CH.

Abstract: Low molecular weight compound exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof:

Abstract: An object of the present invention is to provide a novel low molecular weight compound exhibiting an osteogenesis-promoting action. This object is achieved by a compound having the general formula (I) or a pharmacologically acceptable salt thereof. In the general formula (I), R1 and R2 represent hydrogen atoms, and the like; R3 represents a hydrogen atom, and the like; X, Y, and Z represent nitrogen atoms, and the like; A represents a phenylene group, and the like; n represents 1 or 2, and the like; and V and W represent oxygen atoms, and the like.

Abstract: Low molecular weight compound exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof:

Abstract: Compounds exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof: wherein A is selected from among a 3- to 10-membered heterocyclyl group, B is selected from among an amino group, and X is selected from N and CH.

Abstract: The seat belt device includes a first unit, a second unit, seat belt webbing, a spindle, a first pretensioner, a second pretensioner, and a controller. The first unit determines a possible collision of an automobile in response to a manipulation of the automobile by a driver. The second unit detects the collision of the automobile. The first pretensioner has a motor to rotate in response to a signal indicative of the possible collision determined by the first unit. The second pretensioner is pyrotechnically driven to rotate in response to a signal indicative of the collision detected by the second unit. The controller is configured to cancel an operation of the first pretensioner after an activation of the second pretensioner. The first pretensioner includes a limiter for restricting the motor from transmitting a driving force to the spindle exceeding a predetermined threshold.

Abstract: The seat belt device includes a first unit, a second unit, seat belt webbing, a spindle, a first pretensioner, a second pretensioner, and a controller. The first unit determines a possible collision of an automobile in response to a manipulation of the automobile by a driver. The second unit detects the collision of the automobile. The first pretensioner has a motor to rotate in response to a signal indicative of the possible collision determined by the first unit. The second pretensioner is pyrotechnically driven to rotate in response to a signal indicative of the collision detected by the second unit. The controller is configured to cancel an operation of the first pretensioner after an activation of the second pretensioner. The first pretensioner includes a limiter for restricting the motor from transmitting a driving force to the spindle exceeding a predetermined threshold.

Abstract: A 1-methylcarbapenem compound represented by the formula (I): having antibacterial activity, pharmacologically acceptable esters or salts thereof and pharmaceutical compositions (particularly antibacterial agents) containing them as an active ingredient are described. In addition, the invention includes the use of these compounds, ester derivatives or salts for the manufacture of pharmaceutical compositions, or a method for the prevention or treatment of diseases (particularly bacterial infections) by administering a pharmacologically effective amount of the compounds, ester derivatives or salts to warm-blooded animals (particularly human beings).